PEDIAZOLE (erythromycin ethylsuccinate; sulfisoxazole acetyl) by Teva is clinical pharmacology: orally administered erythromycin ethylsuccinate suspensions are readily and reliably absorbed. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1979.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
PEDIAZOLE is an oral combination antibiotic granule containing erythromycin ethylsuccinate and sulfisoxazole acetyl, approved in 1979. It treats Chlamydia trachomatis infections (conjunctivitis in newborns, pneumonia, urogenital infections), Ureaplasma urealyticum infections, and infections in penicillin-allergic patients. The drug works through dual mechanisms: erythromycin inhibits bacterial protein synthesis via 50S ribosomal binding, while sulfisoxazole acts as a sulfonamide with complementary coverage.
Product approaching end-of-life with limited market presence; expect focused maintenance efforts and potential rationalization of brand team resources.
CLINICAL PHARMACOLOGY: Orally administered erythromycin ethylsuccinate suspensions are readily and reliably absorbed. Erythromycin ethylsuccinate products have demonstrated rapid and consistent absorption in both fasting and nonfasting conditions. However, higher serum concentrations are obtained…
Worked on PEDIAZOLE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PEDIAZOLE offers minimal career upside due to its LOE-approaching status and lack of innovation pipeline. Positions are primarily focused on managing declining revenue and regulatory compliance rather than growth initiatives.